Antibody Libraries Using Segmented Framework Regions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The design of therapeutic antibodies, such as VHH antibodies, is challenging due to the need to balance immunological effects with efficacy, and existing technologies lack effective methods for generating antibodies with high specificity and affinity for therapeutic applications.
Innovation Solution
The development of antibodies or antibody fragments comprising specific CDR sequences, with at least 90% identity to provided sequences, and the creation of nucleic acid libraries encoding for these antibodies, which include variant sequences for CDR regions to enhance binding affinity and diversity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional antibody design methods are used, then the design process is simplified, but the binding affinity and specificity are insufficient for therapeutic applications
Solution Approach 1:
The antibody design process is segmented into distinct modules: framework regions (FR1-FR4) and complementarity-determining regions (CDR1-CDR3). This segmentation allows independent optimization of each region's contribution to binding affinity while maintaining overall structural integrity, resolving the contradiction between achieving high precision binding and managing design complexity
Solution Approach 2:
The patent systematically varies key parameters including CDR sequence compositions, CDR lengths, and framework region sequences to optimize binding affinity. By changing these parameters in a controlled manner and evaluating their effects, the patent achieves high-specificity binding while providing a systematic approach that manages design complexity through structured parameter exploration
2Reliability
If single domain antibodies (VHH) are used, then the therapeutic efficacy is improved, but the balance with immunological effects becomes challenging
Solution Approach 1:
The patent applies local quality by concentrating the antigen-binding specificity entirely within the CDR regions of the VHH domain, while the framework regions provide structural support and stability. This localized functional differentiation allows the VHH to achieve high therapeutic efficacy through optimized CDR-antigen interactions while maintaining compatibility with immunological systems through the stabilizing framework structure
Solution Approach 2:
The patent optimizes specific parameters of the VHH structure including the length and composition of CDR regions, the stability of framework regions, and the overall domain architecture. By systematically adjusting these parameters, the patent achieves both high therapeutic efficacy and appropriate immunological balance, as evidenced by the specific sequence requirements and structural constraints defined in the claims
3Manufacturing precision
If nucleic acid libraries with high diversity are created, then the probability of finding high-affinity antibodies increases, but the library complexity and screening difficulty increase
Solution Approach 1:
The nucleic acid library is segmented into fixed framework regions and variable CDR regions. This segmentation allows the library to maintain high diversity in the CDR regions (encoding binding specificity) while keeping the framework regions constant (providing structural consistency). This resolves the contradiction by concentrating diversity where it is most useful for affinity optimization without proportionally increasing overall library complexity
Solution Approach 2:
The patent uses universal framework regions that can accommodate multiple different CDR sequences while maintaining proper antibody folding and stability. This universal framework design allows a single framework sequence to support diverse CDR combinations, thereby increasing the effective binding affinity diversity without proportionally increasing the total library complexity and screening burden
Data Source
AI summary
Provided herein are methods and compositions relating to variant nucleic acid libraries encoding for antibodies including single domain antibodies. Libraries generated using methods described herein have improved characteristics including improved binding affinity. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.